Zaltrius has collaborated with biopharmaceutical companies as a supplier in the development and manufacturing of vaccines in response to outbreaks and pandemics of infectious diseases such as Ebola, Zika, and H1N1 over the past decade. Zaltrius's experience and solution portfolio will support customers at all stages of vaccine development against the novel coronavirus SARS-CoV-2 outbreak, from discovery to testing and large-scale manufacturing. We provide solutions to help you manage various risks in vaccine development and manufacturing while maintaining speed, quality, and flexibility in emergency situations.

In response to the spread of the novel coronavirus infection, Sartorius Japan will continuously inform you about the measures we are taking. Information on novel coronavirus measures https://sartorius-if.smktg.jp/public/seminar/view/218

The Sartorius brand has been providing innovative products and solutions to support scientists and engineers around the world for 150 years. On February 17, 2020, we are pleased to announce that we have renewed our trademark. After a long period of discussion and preparation, our brand identity has been revitalized. In this renewal, we have updated the brand design at both the group and departmental levels, launching a new logo and a simpler brand architecture. Additionally, we would like to draw your attention to the fact that we have updated our new corporate message to "Simplify Progress." As the new message suggests, our products and technologies aim to simplify your operations and contribute to the acceleration of advancements in medicine.